Mizzou Students Throw Support Behind Medical Pot Initiative: 'It's Just a Plant'
*By Carlo Versano*
On Tuesday, Missouri could become the 32nd state in the U.S. to legalize medical marijuana.
On the ballot are three proposals on the issue ー regarding regulation, taxation, and the distribution of tax revenues. The amendments are byzantine and confusing, but if one passes, medical marijuana will become the law of the land in the "Show-Me" State.
Cannabis legalization has garnered more public support in recent years, and medical pot is often thought to be the gateway to fuller legalization. While the Missouri medical community is [split](https://kcmedicine.org/survey-results-physician-attitudes-medical-marijuana/) on the drug's medicinal value, much of the student body at the University of Missouri has a pro-legalization stance.
CheddarU went to Mizzou's campus to hear what students had to say ahead of the vote.
"I just can't see any good reason not to have it medicinally available here," said In'lana Henderson, VP of Students for Sensible Drug Policy at Mizzou.
"People think that it's very taboo here," she added.
That possibility that Missouri, a reliably red state in the country's heartland, could pass a progressive drug law, gives some students hope that the end result could galvanize public support for cannabis legalization.
"I think that if we can legalize it, it will help other states do that, too," freshman Payton Nichols-Pittman said.
Or, as senior Meg Rogers put it: "It's just something that we don't need to make people feel bad for."
She added: "It's just a plant."
Americans are still spending, but rising anxiety over jobs, AI, housing and tariffs tells a different story. Kearney Consumer Institute’s Katie Thomas explains.
Disney is back in focus after Q3 earnings. Investors are watching streaming profits, theme parks and ESPN as the entertainment giant looks for its next catalyst
Healthcare policy is shifting fast, raising questions about drug prices, Medicare and access. Leap Health CEO Hani Elias explains what patients need to know.
The U.S. job market is cooling as hiring slows and employers turn cautious. LinkedIn’s Kory Kantenga breaks down jobs, wages, spending and AI’s impact.
AI is entering a new phase as enterprises move beyond experimentation and demand measurable returns. Appian CEO Matt Calkins discusses what comes next.
Commercial Metals CEO Peter Matt reveals how a $2.5B acquisition spree is transforming the 111-year-old steelmaker into a construction solutions powerhouse.
Angelo Zino, Senior Vice President and Technology Equity Research Analyst at CFRA, breaks down Big Tech earnings, AI spending, and what's next for the Mag 7.
